US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Emera Inc.

45.66

+0.52001.15%

Post-market: 45.660.00000.00%16:38 EDT

Volume:57.92K

Turnover:2.64M

Market Cap:13.60B

PE:22.07

High:45.76

Open:45.07

Low:45.07

Close:45.14

Loading ...

Overview Company News Filings

HBAR Price Rallies 20% After $230 Million Inflow from Traders in a Week

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

BMO Capital Sticks to Its Buy Rating for Emera (EMA)

Press Release: Emera Incorporated Announces Dividend Rates for Series A and Series B First Preferred Shares

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Valneva’s Chikungunya Vaccine Restriction Lifted by EMA

Ethena (ENA) Hits 30-Day High as Spot and Futures Demand Surge

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference

Press Release: Emera Declares Quarterly Dividends

Cardano Shorts' Bloodbath Triggers 4,146% Liquidation Imbalance in One Hour

Emera Teleconference on August 8 to Discuss Q2 2025 Results

3 Made In China Coins to Watch for the Third Week of July

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

XRP's Crucial 10% Move to Start Bull Run, Shiba Inu (SHIB) Gives Bulls Hope, Ethereum (ETH): Breakout to $3,000 Begins

Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?

Press Release: Emera Incorporated Announces Conversion Privilege of Cumulative Rate Reset First Preferred Shares, Series A and Cumulative Floating Rate First Preferred Shares, Series B

Four new option listings and three option delistings on July 9th

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/EMA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":45.66,"timestamp":1752868800000,"preClose":45.14,"halted":0,"volume":57917,"hourTrading":{"tag":"盘后","latestPrice":45.66,"preClose":45.66,"latestTime":"16:38 EDT","volume":17290,"amount":788399.93054,"timestamp":1752871099207},"delay":0,"floatShares":297632664,"shares":297900000,"eps":2.069006,"marketStatus":"Market Closed","change":0.52,"latestTime":"07-18 16:00:00 EDT","open":45.07,"high":45.76,"low":45.07,"amount":2639189.308658,"amplitude":0.015286,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.069006,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":45.14,"dividendRate":0.046416,"postHourTrading":{"tag":"盘后","latestPrice":45.66,"preClose":45.66,"latestTime":"16:38 EDT","volume":17290,"amount":788399.93054,"timestamp":1752871099207},"volumeRatio":0.6545669474241474,"impliedVol":0,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":297632664,"roa":"2.73%","roe":"7.21%","lyrEps":1.186627,"volumeRatio":0.6545669474241474,"shares":297900000,"dividePrice":2.100704,"high":45.76,"amplitude":0.015286,"preClose":45.14,"low":45.07,"week52Low":43.9012,"pbRate":"1.52","psRate":"2.38","week52High":46.45,"institutionHeld":0,"latestPrice":45.66,"eps":2.069006,"divideRate":0.046008,"volume":57917,"delay":0,"ttmEps":2.069006,"open":45.07,"prevYearClose":45.28,"prevWeekClose":46.07,"prevMonthClose":45.82,"prevQuarterClose":45.82,"fiveDayClose":46.07,"twentyDayClose":44.49,"earningDate":1754582400000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552499745","title":"HBAR Price Rallies 20% After $230 Million Inflow from Traders in a Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2552499745","media":"BE[IN]CRYPTO","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552499745?lang=en_us&edition=fundamental","pubTime":"2025-07-18 21:00","pubTimestamp":1752843600,"startTime":"0","endTime":"0","summary":"HBAR has surged by 20% in the last 24 hours, reaching a 5-month high, driven by a $230 million increase in open interest and rising trader confidence.The Golden Cross between HBAR’s 50-day and 200-day EMAs signals a shift from bearish to bullish momentum, supporting further price gains.HBAR is holding a critical support level at $0.267, and a push above $0.314 could lead to a rise toward $0.375. However, profit-taking risks remain, with a drop to $0.241 possible.HBAR, the native cryptocurrency of the Hedera network, has experienced a significant 20% price jump over the last 24 hours, reaching a 5-month high.This surge in value comes after a period of sustained growth, driven by both positive market sentiment and increased activity in the derivatives market.However, the risk of selling remains. Should HBAR experience a wave of profit-taking from investors, the price could fall back","market":"us","thumbnail":"https://beincrypto.com/wp-content/uploads/2024/04/bic_Hedera_HBAR_3-covers_neutral-850x478.jpg.optimal.jpg","type":0,"news_type":0,"thumbnails":["https://beincrypto.com/wp-content/uploads/2024/04/bic_Hedera_HBAR_3-covers_neutral-850x478.jpg.optimal.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://beincrypto.com/hbar-price-rallies-after-inflow-from-trader/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"beincrypto_highlight","symbols":["EMA","OI","BK4126","BK4081"],"gpt_icon":0},{"id":"2552012462","title":"Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2552012462","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552012462?lang=en_us&edition=fundamental","pubTime":"2025-07-18 19:30","pubTimestamp":1752838200,"startTime":"0","endTime":"0","summary":"CELEBRATION, Fla., July  18, 2025  (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living wi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/18/3117839/16626/en/Zevra-Therapeutics-Announces-MIPLYFFA-and-OLPRUVA-Presentations-at-the-Annual-Meeting-of-the-Southeastern-Regional-Genetics-Group-SERGG.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4124","BK4081","BK4007","CPS","ZVRA","AS","BK4202","BSA","EMA"],"gpt_icon":0},{"id":"2552457753","title":"BMO Capital Sticks to Its Buy Rating for Emera (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2552457753","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552457753?lang=en_us&edition=fundamental","pubTime":"2025-07-18 15:05","pubTimestamp":1752822309,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Benjamin Pham from BMO Capital reiterated a Buy rating on Emera, with a price target of C$65.00. The company’s shar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bmo-capital-sticks-to-its-buy-rating-for-emera-ema-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bmo-capital-sticks-to-its-buy-rating-for-emera-ema-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BMO"],"gpt_icon":0},{"id":"2552812759","title":"Press Release: Emera Incorporated Announces Dividend Rates for Series A and Series B First Preferred Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2552812759","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552812759?lang=en_us&edition=fundamental","pubTime":"2025-07-17 01:15","pubTimestamp":1752686100,"startTime":"0","endTime":"0","summary":"Emera Incorporated   announced today the applicable dividend rates for its Cumulative Rate Reset First Preferred Shares, Series A  and Cumulative Floating Rate First Preferred Shares, Series B , in each case, payable if, as and when declared by the Board of Directors of the Company:. quarter), being equal to the sum of the Government of Canada bond yield. as at July 16, 2025, plus 1.84%, payable quarterly on the 15th of. February, May, August and November of each year during the five-year. period commencing on August 15, 2025 and ending on . The conversion of Series A Shares is subject to the conditions that:  if the Company determines, after having taken into account all shares tendered for conversion by holders of Series A Shares that there would remain outstanding on the Conversion Date less than 1,000,000 Series A Shares, all remaining Series A Shares will automatically be converted into Series B Shares on a one-for-one basis on the Conversion Date, and  alternatively, if the Compa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EMA"],"gpt_icon":0},{"id":"2551140383","title":"Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism","url":"https://stock-news.laohu8.com/highlight/detail?id=2551140383","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551140383?lang=en_us&edition=fundamental","pubTime":"2025-07-16 19:30","pubTimestamp":1752665400,"startTime":"0","endTime":"0","summary":"CELEBRATION, Fla., July  16, 2025  (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living wi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/16/3116288/16626/en/Zevra-Therapeutics-Announces-Open-Label-Extension-Data-Showing-Sustained-Long-Term-Efficacy-of-MIPLYFFA-for-the-Treatment-of-NPC-Published-in-the-Journal-of-Molecular-Genetics-and-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ZVRA","EMA","BK4081"],"gpt_icon":0},{"id":"2551169711","title":"Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film","url":"https://stock-news.laohu8.com/highlight/detail?id=2551169711","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551169711?lang=en_us&edition=fundamental","pubTime":"2025-07-15 19:00","pubTimestamp":1752577200,"startTime":"0","endTime":"0","summary":"New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July  15, 2025  (GLOBE N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/15/3115450/0/en/Aquestive-Therapeutics-Provides-International-Expansion-Update-for-Anaphylm-epinephrine-Sublingual-Film.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AQST","BK4539","LENZ","EMA","BK4215","MAA","BK4007","BK4585","BK4588","BK4139","BK4081"],"gpt_icon":0},{"id":"2551931189","title":"Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in  Familial Adenomatous Polyposis (FAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2551931189","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551931189?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:30","pubTimestamp":1752496200,"startTime":"0","endTime":"0","summary":"July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in  Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/14/3114750/0/en/Biodexa-Announces-Filing-of-CTA-in-Europe-for-Phase-3-Serenta-Trial-in-Familial-Adenomatous-Polyposis-FAP.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4081","EMA","BDRX","CTA"],"gpt_icon":0},{"id":"2550965124","title":"Valneva’s Chikungunya Vaccine Restriction Lifted by EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2550965124","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550965124?lang=en_us&edition=fundamental","pubTime":"2025-07-12 02:28","pubTimestamp":1752258488,"startTime":"0","endTime":"0","summary":"Valneva ( ($VALN) ) just unveiled an update. On July 11, 2025, Valneva announced that the European Medicines Agency (EMA) lifted the temporary rest...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/valnevas-chikungunya-vaccine-restriction-lifted-by-ema?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/valnevas-chikungunya-vaccine-restriction-lifted-by-ema?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"gpt_icon":0},{"id":"2550378959","title":"Ethena (ENA) Hits 30-Day High as Spot and Futures Demand Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2550378959","media":"BE[IN]CRYPTO","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550378959?lang=en_us&edition=fundamental","pubTime":"2025-07-11 20:00","pubTimestamp":1752235200,"startTime":"0","endTime":"0","summary":"Bitcoin’s all-time high fuels altcoin rally, with Ethena’s ENA surging 25% in 24 hours, making it the top gainer.Spot inflows into ENA reached $3.46 million, the highest in two months, reflecting growing investor confidence.ENA’s futures open interest surged 8%, signaling bullish sentiment and positioning for further price increases.Bitcoin’s explosive rally to a new all-time high above $117,000 has triggered a market-wide resurgence in trading activity, lifting altcoins.One of the biggest beneficiaries of this bullish wave is Ethena’s native token ENA, which has surged 25% in the past 24 hours. This makes it the top gainer in the market today.ENA Leads the Charge as Spot Demand and Derivatives Activity Explode. Now trading at its highest level in 30 days, ENA’s rally comes with a significant spike in investor interest. Spot inflows into the altcoin have surged to a two-month high, signaling a rapid increase in demand from traders looking to ride the bullish momentum of the past 24 hou","market":"nz","thumbnail":"https://beincrypto.com/wp-content/uploads/2025/05/bic_altcoin_coin_1-covers_bullish-850x478.jpg.optimal.jpg","type":0,"news_type":0,"thumbnails":["https://beincrypto.com/wp-content/uploads/2025/05/bic_altcoin_coin_1-covers_bullish-850x478.jpg.optimal.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://beincrypto.com/ena-price-rockets-as-bitcoin-rallies/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"beincrypto_highlight","symbols":["BK4081","BTC.USD.CC","BTC.USD.HKCC","EMA"],"gpt_icon":0},{"id":"2550958304","title":"Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2550958304","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550958304?lang=en_us&edition=fundamental","pubTime":"2025-07-11 19:30","pubTimestamp":1752233400,"startTime":"0","endTime":"0","summary":"CELEBRATION, Fla., July  11, 2025  (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/11/3113931/16626/en/Zevra-Therapeutics-Announces-MIPLYFFA-arimoclomol-Featured-in-Presentations-at-the-National-Niemann-Pick-Disease-Foundation-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZVRA","NHLD","BK4007","BK4081","EMA"],"gpt_icon":0},{"id":"2550738931","title":"Press Release: Emera Declares Quarterly Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=2550738931","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550738931?lang=en_us&edition=fundamental","pubTime":"2025-07-11 18:00","pubTimestamp":1752228000,"startTime":"0","endTime":"0","summary":"On July 11, 2025, the Board of Directors of Emera Inc.  declared quarterly dividends on its common shares and First Preferred Shares, each of which is payable on and after August 15, 2025 to the applicable shareholders of record at the close of business on August 1, 2025, as follows:. This news release contains forward-looking information within the meaning of applicable securities laws, including without limitation, statements about Emera's quarterly dividends. By its nature, forward-looking information requires Emera to make assumptions and is subject to inherent risks and uncertainties. These statements reflect Emera management's current beliefs and are based on information currently available to Emera management. There is a risk that predictions, forecasts, conclusions and projections that constitute forward-looking information will not prove to be accurate, that Emera's assumptions may not be correct and that actual results may differ materially from such forward-looking informati","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EMA"],"gpt_icon":0},{"id":"2550399441","title":"Cardano Shorts' Bloodbath Triggers 4,146% Liquidation Imbalance in One Hour","url":"https://stock-news.laohu8.com/highlight/detail?id=2550399441","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550399441?lang=en_us&edition=fundamental","pubTime":"2025-07-11 12:15","pubTimestamp":1752207300,"startTime":"0","endTime":"0","summary":"Cardano (ADA) has joined the ongoing cryptocurrency rally as the price spiked by over 15% in the last 24 hours. This has triggered a staggering 4,146% liquidation imbalance in one hour as short positi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/cardano-shorts-bloodbath-triggers-4146-liquidation-imbalance-in-one-hour","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["ATH","ADA.AU","BTC.USD.HKCC","BK7067","ATH.AU","EMA","BK7016","BTC.USD.CC","BK4081","BK4162"],"gpt_icon":0},{"id":"2550603446","title":"Emera Teleconference on August 8 to Discuss Q2 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2550603446","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550603446?lang=en_us&edition=fundamental","pubTime":"2025-07-11 02:30","pubTimestamp":1752172200,"startTime":"0","endTime":"0","summary":"HALIFAX, Nova Scotia, July 10, 2025----Today Emera  announced that it will release its Q2 2025 results on Friday, August 8, 2025, before markets open. The Company will host a teleconference and webcast the same day at 9:30 a.m. Atlantic  to discuss the results.Emera  is a leading North American provider of energy services headquartered in Halifax, Nova Scotia, with investments in regulated electric and natural gas utilities, and related businesses and assets. The Emera family of companies delivers safe, reliable energy to approximately 2.6 million customers in the United States, Canada and the Caribbean. Our team of 7,600 employees is committed to our purpose of energizing modern life and delivering a cleaner energy future for all. Emera’s common and preferred shares are listed and trade on the Toronto Stock Exchange and its common shares are listed and trade on the New York Stock Exchange. Additional information can be accessed at www.emera.com, on SEDAR+ at www.sedarplus.ca and on ED","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/emera-teleconference-august-8-discuss-183000602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4081","EMICF","EMA"],"gpt_icon":0},{"id":"2550662622","title":"3 Made In China Coins to Watch for the Third Week of July","url":"https://stock-news.laohu8.com/highlight/detail?id=2550662622","media":"BE[IN]CRYPTO","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550662622?lang=en_us&edition=fundamental","pubTime":"2025-07-10 07:00","pubTimestamp":1752102000,"startTime":"0","endTime":"0","summary":"Huobi Token  saw a 23% rise in the past week, with RSI indicating growing buy-side pressure and a potential price rise to $0.29.Nervos Network's CKB surged 13%, supported by strong uptrend signals from the Aroon Up indicator, suggesting further price gains toward $0.0040.Zilliqa  gained 4%, trading above the 20-day EMA, signaling bullish momentum and the potential for further growth to $0.0116.With the cryptocurrency market continuing to experience volatility this week, investor interest may be shifting toward regional narratives and specific ecosystem tokens.Among the standouts are coins with strong development ties to China, often dubbed “Made in China” tokens. They include Huobi Token , Nervos Network , and Zilliqa .HT’s RSI readings indicate market participants prefer accumulation over distribution. If this trend continues, its price could climb to $0.29.ZIL trades at $0.0108, noting a 4% price uptick in the past seven days. Its steady rally has pushed the price above the 20-day ex","market":"nz","thumbnail":"https://beincrypto.com/wp-content/uploads/2025/02/bic_altcoins_alt_coins-covers_neutral-5-850x478.jpg.optimal.jpg","type":0,"news_type":0,"thumbnails":["https://beincrypto.com/wp-content/uploads/2025/02/bic_altcoins_alt_coins-covers_neutral-5-850x478.jpg.optimal.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://beincrypto.com/made-in-china-coins-watch-july-second-week/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"beincrypto_highlight","symbols":["BK4181","BK4150","BK4218","BK4081","EMA","HT","RSI"],"gpt_icon":0},{"id":"2550766821","title":"Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2550766821","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550766821?lang=en_us&edition=fundamental","pubTime":"2025-07-10 04:01","pubTimestamp":1752091260,"startTime":"0","endTime":"0","summary":"Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and W","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/09/3112864/0/en/Nurix-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250843.SGD","WM","IE00BLSP4452.SGD","LU0321505439.SGD","LU2362541513.USD","BK4581","SG9999013999.USD","LU2229751404.USD","IE00B19Z3B42.SGD","BK4588","LU1923621640.USD","CR","LU2298064838.USD","LU0289961442.SGD","LU1917777945.USD","LU2023250504.SGD","ODD","LU1023059063.AUD","BK4566","LU0058720904.USD","BK4599","IE00B19Z3581.USD","LU1066051498.USD","LU2413666426.HKD","SG9999002224.SGD","IE0009354923.USD","LU2092937221.SGD","LU0306807586.USD","BK4585","EMA","SGXZ57979304.SGD","LU1989772840.SGD","LU0456855351.SGD","LU0689626769.HKD","LU0347712357.USD","LU1892829315.USD","LU1894683348.USD","NRIX","LU1066053197.SGD","LU2211814178.USD","LU0175139822.USD","LU1712237335.SGD","ORR","LU2355687059.USD","LU2240825500.USD","LU0289960550.SGD","CNS","LU2041044095.USD"],"gpt_icon":1},{"id":"2550989920","title":"XRP's Crucial 10% Move to Start Bull Run, Shiba Inu (SHIB) Gives Bulls Hope, Ethereum (ETH): Breakout to $3,000 Begins","url":"https://stock-news.laohu8.com/highlight/detail?id=2550989920","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550989920?lang=en_us&edition=fundamental","pubTime":"2025-07-10 00:01","pubTimestamp":1752076860,"startTime":"0","endTime":"0","summary":"After a 10% rally from the beginning of the month, XRP has entered a crucial technical zone, giving investors the kind of decisive action they have been waiting for as July gets underway. According to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/xrps-crucial-10-move-to-start-bull-run-shiba-inu-shib-gives-bulls-hope-ethereum-eth-breakout-to","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["BK1611","ETHV","EZET","09046","RSI","BK4211","HOPE","03046","03179","09009","FETH","ETH.USD.HKCC","EMA","QETH","03009","CETH","BK4081","ETH.USD.CC","LDO.USD.HKCC","BK4601","09179","ETH","BK4150"],"gpt_icon":0},{"id":"2550442625","title":"Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?","url":"https://stock-news.laohu8.com/highlight/detail?id=2550442625","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550442625?lang=en_us&edition=fundamental","pubTime":"2025-07-09 23:48","pubTimestamp":1752076080,"startTime":"0","endTime":"0","summary":"Novo NordiskNVO announced that it has submitted a regulatory application to the European Medicines Agency  seeking approval for a new and higher dose of its popular obesity medication, Wegovy. Wegovy is also indicated for major adverse cardiovascular events risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis.Novo Nordisk also markets semaglutide as Ozempic injection and Rybelsus oral tablet for type II diabetes . The EMA submission is backed by data from the STEP UP and STEP UP T2D studies, which evaluated semaglutide 7.2 mg in obese adult patients, with and without T2D. In the STEP UP study, the higher dose of Wegovy led to an average weight loss of 21%, with one-third of participants shedding at least 25% of their body weight compared with placebo. The 7.2 mg dose was well-tolerated and demonstrated a favorable safety profile, aligning with that of the 2.4 mg dose and previous semaglutide studies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novo-nordisk-increasing-dosage-defend-154800545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1127390331.HKD","BK4532","SG9999014914.USD","LU0689472784.USD","LU1868837136.USD","LU0456855351.SGD","LU0094547139.USD","SG9999018865.SGD","LU2552382132.HKD","LU2237443978.SGD","SGXZ57979304.SGD","LU0889565916.HKD","BK4534","IE00BKVL7J92.USD","LU2456880835.USD","LU1548497426.USD","LU2471134796.USD","SG9999013999.USD","LU2023250504.SGD","LU0238689110.USD","LU2602419157.SGD","SG9999014898.SGD","LU1868836591.USD","LU0256863902.USD","LU0320765059.SGD","LU2236285917.USD","LU2361044865.SGD","LU0882574055.USD","LU2237443622.USD","NVO","LU2552382215.SGD","SG9999015986.USD","LU0385154629.USD","SG9999015978.USD","LU0203202063.USD","VKTX","LU1917777945.USD","EMA","IE00B1BXHZ80.USD","LU1623119135.USD","LU1069344957.HKD","SG9999001176.SGD","IE00BJLML261.HKD","BK4599","LU2237443465.HKD","LU1989771016.USD","LU1064131342.USD","BK4588","SG9999018857.SGD"],"gpt_icon":1},{"id":"2550659872","title":"Press Release: Emera Incorporated Announces Conversion Privilege of Cumulative Rate Reset First Preferred Shares, Series A and Cumulative Floating Rate First Preferred Shares, Series B","url":"https://stock-news.laohu8.com/highlight/detail?id=2550659872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550659872?lang=en_us&edition=fundamental","pubTime":"2025-07-09 23:00","pubTimestamp":1752073200,"startTime":"0","endTime":"0","summary":"Emera Incorporated   announced today that it does not intend to exercise its right to redeem all or any part of the currently outstanding Cumulative Rate Reset First Preferred Shares, Series A  or the Cumulative Floating Rate First Preferred Shares, Series B  of the Company on August 15, 2025. There are currently 4,866,814 Series A Shares and 1,133,186 Series B Shares outstanding.As a result, subject to certain conditions set out in the prospectus supplement of the Company dated May 26, 2010, to the short form base shelf prospectus of the Company dated May 19, 2010, relating to the issuance of the Series A Shares and Series B Shares , on August 15, 2025 :.  the holders of Series A Shares have the right, at their option:. to retain any or all of their Series A Shares and continue to receive a. to convert any or all of their Series A Shares, on a one-for-one basis,In either case, Emera will give written notice to that effect","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081"],"gpt_icon":0},{"id":"2550637024","title":"Four new option listings and three option delistings on July 9th","url":"https://stock-news.laohu8.com/highlight/detail?id=2550637024","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550637024?lang=en_us&edition=fundamental","pubTime":"2025-07-09 20:36","pubTimestamp":1752064594,"startTime":"0","endTime":"0","summary":"New option listings for July 9th include DTCBD Stock (DTCBD), Everus Construction Group Inc (ECG), Emera Incorporated (EMA), and Unity Biotechnolog...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/four-new-option-listings-and-three-option-delistings-on-july-9th-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/four-new-option-listings-and-three-option-delistings-on-july-9th-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4129","EMA","BK4081","ECG"],"gpt_icon":0},{"id":"2550637201","title":"Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2550637201","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550637201?lang=en_us&edition=fundamental","pubTime":"2025-07-09 20:35","pubTimestamp":1752064500,"startTime":"0","endTime":"0","summary":"Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/09/3112575/0/en/Moleculin-Expands-Phase-3-MIRACLE-Clinical-Trial-into-the-Country-of-Georgia-Enrollment-Update-and-Future-Plans.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","CTA","BK4081","EMA"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":65,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"date":"2025-08-08","symbol":"EMA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":null,"defaultRemindTime":1754640000000,"name":null,"time":"Pre-Market","dateTimestamp":1754625600000,"actualEps":null},{"date":"2025-08-01","symbol":"EMA","amount":0.725,"announcedDate":"2025-07-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-01","defaultRemindTime":1754055000000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-15","payableDate":"2025-08-01","currency":"CAD","dateTimestamp":1754020800000,"payDate":"2025-08-15"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2015-07-29","recordDate":"2015-07-31","paymentDate":"2015-08-17","value":0.305564,"currency":"USD"},{"executeDate":"2015-10-29","recordDate":"2015-11-02","paymentDate":"2015-11-16","value":0.3565682,"currency":"USD"},{"executeDate":"2016-01-29","recordDate":"2016-02-02","paymentDate":"2016-02-16","value":0.3421147,"currency":"USD"},{"executeDate":"2016-04-28","recordDate":"2016-05-02","paymentDate":"2016-05-16","value":0.3682105,"currency":"USD"},{"executeDate":"2016-07-20","recordDate":"2016-07-22","paymentDate":"2016-08-15","value":0.4045038,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.0667,"buy":0.4,"hold":0.4667,"sell":0,"strongSell":0.0667,"meanLabel":"HOLD","meanPercent":0.4667,"analysts":15,"updateTime":1750996800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2025-07-18","current":19.592532,"percent":0.545455,"low":19.106036,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"high":19.892644,"avg":19.509467,"sd":0.223852,"marketCap":13439260670.95},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95}],"updateTime":1752923833821}}}